Compare Amphastar Pharmaceuticals Inc (AMPH) vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.48 (market cap $826.08M), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $245.59 (market cap $45.15B). The key difference: TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is far larger — about 54.7× Amphastar Pharmaceuticals Inc's market cap, and TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | TTWO | |
|---|---|---|
Market Cap | $826.08M | $45.15B |
Sector | Health | Media |
52-Week High | $30.81 | $262.29 |
52-Week Low | $16.87 | $189.69 |
Enterprise Value | $1.22B | $46.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Take-Two Interactive (TTWO) trades at $243.20, down 1.18% on the day, with a bullish technical outlook and strong analyst support. The stock shows consistent earnings beats, including Q1 2026 EPS of $0.80 versus $0.563 expected, and benefits from positive sentiment around Grand Theft Auto VI pre-orders. However, fundamentals reveal challenges with a net income margin of -4.48% and negative ROE of -10.56%, though revenue grew to $5.63B in 2025. Cash flow improved with net cash flow of $457.20M in 2025, driven by financing activities.
The outlook is optimistic due to GTA VI's upcoming launch, with a consensus price target of $302.50 implying 24% upside. Risks include high debt levels, with debt-to-asset ratio at 39.87% in 2025, and reliance on blockbuster game success. Institutional sentiment is strongly bullish, with 79% of analysts rating Buy, but investors should monitor execution on profitability targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →
